Literature DB >> 12884458

Adalimumab (HUMIRA): a review.

Noah Scheinfeld1.   

Abstract

Adalimumab (HUMIRA, Abbott Laboratories) is a new fully human TNF-alpha monoclonal antibody recently approved for the treatment of rheumatoid arthritis and undergoing trials for use in treating other conditions, including psoriasis and psoriatic arthritis. This article reviews its mechanisms of action, clinical trial results, and related discussion.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12884458

Source DB:  PubMed          Journal:  J Drugs Dermatol        ISSN： 1545-9616            Impact factor:   2.114


  16 in total

Review 1.  Recent insights into the immunopathogenesis of psoriasis provide new therapeutic opportunities.

Authors:  Brian J Nickoloff; Frank O Nestle
Journal:  J Clin Invest       Date:  2004-06       Impact factor: 14.808

2.  Population pharmacokinetics of onercept in healthy subjects.

Authors:  Sophie Glatt; Eliane Fuseau; Mauro Buraglio; Quyen T X Nguyen
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

3.  Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2006.

Authors:  D E Furst; F C Breedveld; J R Kalden; J S Smolen; G R Burmester; P Emery; E C Keystone; M H Schiff; P L C M van Riel; M E Weinblatt; M H Weisman
Journal:  Ann Rheum Dis       Date:  2006-11       Impact factor: 19.103

Review 4.  Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007.

Authors:  D E Furst; F C Breedveld; J R Kalden; J S Smolen; G R Burmester; J Sieper; P Emery; E C Keystone; M H Schiff; P Mease; P L C M van Riel; R Fleischmann; M H Weisman; M E Weinblatt
Journal:  Ann Rheum Dis       Date:  2007-11       Impact factor: 19.103

Review 5.  Safety and tolerability of adalimumab for the treatment of psoriasis: a review summarizing 15 years of real-life experience.

Authors:  Paul Sator
Journal:  Ther Adv Chronic Dis       Date:  2018-05-22       Impact factor: 5.091

Review 6.  Updated consensus statement on biological agents, specifically tumour necrosis factor {alpha} (TNF{alpha}) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005.

Authors:  D E Furst; F C Breedveld; J R Kalden; J S Smolen; G R Burmester; J W J Bijlsma; M Dougados; P Emery; E C Keystone; L Klareskog; P J Mease
Journal:  Ann Rheum Dis       Date:  2005-11       Impact factor: 19.103

Review 7.  Pulmonary complications of tumor necrosis factor-targeted therapy.

Authors:  Krishna Thavarajah; Peggy Wu; Elisa J Rhew; Anjana K Yeldandi; David W Kamp
Journal:  Respir Med       Date:  2009-02-07       Impact factor: 3.415

Review 8.  [Systemic psoriasis therapy - the next step. Adalimumab].

Authors:  G Wozel; M Sticherling
Journal:  Hautarzt       Date:  2007-06       Impact factor: 0.751

Review 9.  Updated consensus statement on biological agents, specifically tumour necrosis factor alpha (TNFalpha) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2004.

Authors:  D E Furst; F C Breedveld; J R Kalden; J S Smolen; G R Burmester; J W J Bijlsma; M Dougados; P Emery; E C Keystone; L Klareskog; P J Mease
Journal:  Ann Rheum Dis       Date:  2004-11       Impact factor: 19.103

Review 10.  Mechanisms, Pathophysiology and Current Immunomodulatory/Immunosuppressive Therapy of Non-Infectious and/or Immune-Mediated Choroiditis.

Authors:  Ioannis Papasavvas; Ilknur Tugal-Tutkun; Carl P Herbort
Journal:  Pharmaceuticals (Basel)       Date:  2022-03-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.